Developer docs
API playgroundTry for free, no card

Search company profiles

Cellino

Full company profile

uuid00004lu

Namestring
Cellino
Legal namestring
Cellino
Websiteurl
cellinobio.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Cellino is a privately held regenerative-medicine biotechnology company headquartered in Cambridge, Massachusetts, founded in 2017 to address the lack of scalable, reproducible manufacturing for personalized cell therapies. Its flagship Nebula™ platform is an AI-driven, closed-loop optical bioprocess that combines deep learning algorithms, label-free imaging, laser-based cell management, and the proprietary Cellinoverse in silico simulation environment on a modular, cassette-based hardware form factor. The platform targets the production of autologous induced pluripotent stem cell (iPSC) therapies for a broad range of chronic degenerative conditions including Parkinson's, diabetes, Alzheimer's, heart disease, kidney disease, and spinal cord injury, with a stated cost-reduction goal of approximately $10,000 per autologous iPSC line by 2030, down from a current $1–3 million baseline.

Cellino's business model is multi-streamed and pre-commercial. Non-dilutive R&D funding comes primarily from a $25 million, five-year ARPA-H NEBULA program award announced in September 2024, while venture capital is anchored by an $80 million Series A closed in January 2022 and led by Leaps by Bayer, 8VC, and Humboldt Fund. Commercial revenue is structured around strategic co-development partnerships with biopharma companies — notably Karis Bio for cardiovascular disease (April 2025) and Matricelf for spinal cord injury (March 2025) — which imply future milestone, licensing, and royalty streams rather than near-term product sales. Distribution is anchored by the U.S.'s first Nebula-powered iPSC Foundry, launched in February 2025, with a longer-term vision of hospital-based, on-demand cassette deployment under NEBULA and a direct patient waitlist on the company website.

Key competitive advantages include the FDA Advanced Manufacturing Technology (AMT) Designation received in May 2025 for its iPSC manufacturing technology, a substantial first-mover infrastructure position in U.S. autologous iPSC foundries, and an integrated AI stack that the company claims can suppress inter-donor variability in autologous tissue production. Risks are concentrated: a small number of biopharma partners and a single government program account for the bulk of near-term counterparties, the company remains pre-revenue with no published pricing, and the $10,000-per-line cost target — central to its investment thesis — has not yet been demonstrated at commercial scale.

Short descriptiontext

Cellino builds the AI-driven Nebula platform for scalable, autologous iPSC biomanufacturing of personalized regenerative cell therapies, serving biopharma partners, hospitals, and ultimately patients with chronic degenerative diseases.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
iPSC biomanufacturing, regenerative medicine, cell therapy manufacturing, autologous cell therapy, bioprocess automation
Industry3 codes
PRIMARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Regenerative Medicine Biomanufacturing
Social media profiles1 record
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model3 records
1Government R&D grants (ARPA-H)
TypeManaged Services
Description

Non-dilutive funding awarded by ARPA-H ($25M over five years under NEBULA) to support development of autonomous biomanufacturing; effectively functions as development-stage revenue tied to milestone delivery.

businesswire.com
2Strategic co-development partnerships with biopharma
TypeLicensing Royalties
Description

Cellino partners with biopharma companies (e.g., Karis Bio for cardiovascular iPSC therapy) to co-develop Nebula-powered autologous iPSC therapies, implying future milestone payments, licensing, or royalty streams.

businesswire.com
3Future autologous iPSC therapy commercialization
TypeTransaction Fee
Description

Long-term commercial intent to deliver personalized regenerative therapies to patients at scale, targeting a per-line cost reduction from $1–$3 million to ~$10,000 by 2030, implying eventual per-treatment or per-line revenue.

longevity.technology
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Technology or R&D, Personnel, Infrastructure, Operations, Supply Chain, Marketing or Sales
Pricing details1 tier
1Not publicly disclosed; pre-commercial pricing roadmap targets ~$10,000 per autologous iPSC line by 2030 (down from current $1–$3M).
ModelOtherBilling cadenceMulti-year contract
Notes

Quote-based / Not publicly disclosed. The $10,000-per-line target is a stated cost-reduction goal, not a published price.

longevity.technology
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Nebula
Description

The company's proprietary AI-driven, modular, cassette-based biomanufacturing platform that compresses traditional infrastructure into scalable systems for producing personalized regenerative cell therapies (iPSC).

businesswire.com
Core offering1 text field

Cellino builds the Nebula™ platform, an AI-driven, closed-loop optical biomanufacturing system for producing autologous iPSC-based regenerative cell, tissue, and organ replacement therapies. The platform combines deep learning, label-free imaging, laser-based cell management, and the Cellinoverse in silico simulation environment, deployed through cassette-based hardware at centralized foundries or in hospitals. The company pursues co-development partnerships with biopharma and, longer term, intends to commercialize per-patient autologous therapies, targeting a reduction in cost per iPSC line from $1–3 million to ~$10,000 by 2030.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Targeted cost reduction from $1–$3 million to approximately $10,000 per autologous iPSC line by 2030
+2 more records
Product overview1 text field

Cellino offers a single unified automated biomanufacturing platform, the Nebula™ Platform, composed of tightly integrated modules: Deep Learning (AI algorithms for reproducible biomanufacturing), Cellinoverse (in silico simulation of bioprocess behavior), Laser Cell Management (laser-based cell-density control), and the Optical Bioprocess (closed-loop, image-guided bioprocess control). Together these modules power the Nebula-Powered iPSC Foundry, the first U.S.-based foundry for scalable autologous biomanufacturing, enabling patient-specific regenerative therapies for conditions such as Parkinson's, diabetes, heart disease, Alzheimer's, kidney disease, and spinal cord injury.

Product and service3 records
1Nebula™ Platform
CategoryCore biomanufacturing platform
Description

Cellino's flagship modular, cassette-based biomanufacturing platform that compresses traditional cell-therapy infrastructure to enable scalable, distributed production of autologous iPSC-based regenerative medicines, deployable as large foundries or in hospitals. It is sold/licensed through co-development partnerships with biopharma and is targeted at hospitals for future point-of-care manufacturing.

2Nebula-Powered iPSC Foundry
CategoryManufacturing facility / foundry deployment
Description

Facility-level deployment of the Nebula platform for scalable autologous biomanufacturing, launched as the U.S.'s first Nebula-Powered iPSC Foundry in February 2025. Operationalizes the Nebula platform as a centralized production and partnership hub serving biopharma co-development partners and future hospital customers.

3NEBULA Hospital-Based Personalized Cell Therapy Manufacturing Program
CategoryHospital point-of-care manufacturing program
Description

Government-funded program under ARPA-H NEBULA to enable hospitals and healthcare facilities to deploy Nebula cassettes for on-demand, point-of-care production of personalized autologous cell therapies targeting heart disease, Parkinson's, and diabetes.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCore Technology/Clinical Research PartnerTypeStrategic or Co-development PartnerAnnounced on2026-04-07
Description

Polyphron and Cellino jointly published results showing Polyphron's platform can manufacture structured human tissue across genetically diverse patient-derived iPSC lines without re-optimizing per donor, validating scalability of autologous tissue manufacturing via computational optimization.

2Karis Bio
Strategic tierCore Co-Development Partner For First Nebula-Powered Cardiovascular TherapyTypeStrategic or Co-development PartnerAnnounced on2025-04-15
Description

Cellino announced a partnership with Karis Bio to develop the first Nebula™-powered autologous iPSC therapy for cardiovascular disease. The partnership leverages Cellino's automated iPSC biomanufacturing platform to produce patient-specific regenerative therapies.

businesswire.com
Strategic tierCore Co-Development Partner For Spinal Cord Injury PipelineTypeStrategic or Co-development PartnerAnnounced on2025-03-11
Description

Cellino and Matricelf announced a global collaboration to scale personalized spinal cord injury treatments using Cellino's Nebula platform for autologous iPSC manufacturing combined with Matricelf's spinal cord regeneration technology.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ElevateBio operates a hub-and-spoke cell and gene therapy platform combining process development and cGMP manufacturing capacity (BaseCamp) with internal therapeutic programs. Its integrated manufacturing-plus-pipeline model closely mirrors Cellino's foundry-plus-co-development strategy for regenerative cell therapies.

TypeBroad incumbent
Description

Thermo Fisher Scientific operates a sizable bioproduction and cell therapy services business, including cell therapy manufacturing capacity through its Patheon and Brammer Bio CDMO acquisitions. It is a broad incumbent competing across the full biomanufacturing stack where Cellino's Nebula platform aims to differentiate on automation and cost.

TypeDirect peer
Description

RoslinCT (formerly Roslin Cells) is a cell therapy contract development and manufacturing organization specializing in iPSC-derived cell therapies, including clinical-grade iPSC line production. It directly competes with Cellino on scalable iPSC manufacturing for clinical and commercial regenerative medicine applications.

4Culture Biosciences
TypeEmerging player
Description

Culture Biosciences offers cloud-based, automated bioreactor infrastructure for bioprocess development and scale-up. It is an emerging player with thematic overlap to Cellino's automated biomanufacturing vision, particularly in applying software and AI to cell culture process optimization, though focused on microbial/mammalian bioprocess rather than autologous iPSC therapies.

TypeDirect peer
Description

Ori Biotech is a London-based cell and gene therapy manufacturing platform company building automated, closed-system bioprocessing hardware for autologous and allogeneic therapies. It is one of the closest direct comparables to Cellino's Nebula platform given its focus on automation and scalability of personalized cell therapy manufacturing.

TypeEmerging player
Description

Ginkgo Bioworks operates a synthetic biology platform combining automated lab infrastructure with cell programming capabilities for industrial and therapeutic applications. It is an emerging player with partial overlap to Cellino's automated, AI-driven cell engineering and biomanufacturing capabilities, though with a broader industrial biology scope.

7Vineti
TypeOthers
Description

Vineti provides a cell and gene therapy orchestration and supply chain platform that manages the workflow, chain of identity, and chain of custody for personalized cell therapies. It is an adjacent ecosystem participant rather than a direct competitor, but its orchestration role is complementary to Nebula's manufacturing focus and could be integrated with Cellino's platform.

TypeBroad incumbent
Description

Lonza is a Swiss global CDMO with one of the largest cell and gene therapy manufacturing footprints worldwide, including dedicated autologous cell therapy facilities. It serves as a broad incumbent that competes with Cellino by offering outsourced cell therapy manufacturing services to biopharma at industrial scale.

TypeBroad incumbent
Description

Cytiva, a Danaher operating company, supplies bioprocessing equipment, consumables, and services for cell therapy manufacturing, including automation platforms. It overlaps with Cellino in the cell therapy bioprocess tooling market and is investing in closed, automated cell therapy manufacturing solutions.

TypeDirect peer
Description

bit.bio is a UK-based synthetic biology company developing a precision cellular reprogramming technology (opti-ox) to produce defined human cell types at scale for research and therapeutic use. It is a direct peer in iPSC-derived cell therapy manufacturing technology, though with a different reprogramming modality.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses2 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights8 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability8 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cellino

Regenerative Medicine Biomanufacturingcellinobio.com

Cellino builds the AI-driven Nebula platform for scalable, autologous iPSC biomanufacturing of personalized regenerative cell therapies, serving biopharma partners, hospitals, and ultimately patients with chronic degenerative diseases.

What Cellino does

Cellino is a privately held regenerative-medicine biotechnology company headquartered in Cambridge, Massachusetts, founded in 2017 to address the lack of scalable, reproducible manufacturing for personalized cell therapies. Its flagship Nebula™ platform is an AI-driven, closed-loop optical bioprocess that combines deep learning algorithms, label-free imaging, laser-based cell management, and the proprietary Cellinoverse in silico simulation environment on a modular, cassette-based hardware form factor. The platform targets the production of autologous induced pluripotent stem cell (iPSC) therapies for a broad range of chronic degenerative conditions including Parkinson's, diabetes, Alzheimer's, heart disease, kidney disease, and spinal cord injury, with a stated cost-reduction goal of approximately $10,000 per autologous iPSC line by 2030, down from a current $1–3 million baseline.

Cellino's business model is multi-streamed and pre-commercial. Non-dilutive R&D funding comes primarily from a $25 million, five-year ARPA-H NEBULA program award announced in September 2024, while venture capital is anchored by an $80 million Series A closed in January 2022 and led by Leaps by Bayer, 8VC, and Humboldt Fund. Commercial revenue is structured around strategic co-development partnerships with biopharma companies — notably Karis Bio for cardiovascular disease (April 2025) and Matricelf for spinal cord injury (March 2025) — which imply future milestone, licensing, and royalty streams rather than near-term product sales. Distribution is anchored by the U.S.'s first Nebula-powered iPSC Foundry, launched in February 2025, with a longer-term vision of hospital-based, on-demand cassette deployment under NEBULA and a direct patient waitlist on the company website.

Key competitive advantages include the FDA Advanced Manufacturing Technology (AMT) Designation received in May 2025 for its iPSC manufacturing technology, a substantial first-mover infrastructure position in U.S. autologous iPSC foundries, and an integrated AI stack that the company claims can suppress inter-donor variability in autologous tissue production. Risks are concentrated: a small number of biopharma partners and a single government program account for the bulk of near-term counterparties, the company remains pre-revenue with no published pricing, and the $10,000-per-line cost target — central to its investment thesis — has not yet been demonstrated at commercial scale.

Cellino firmographics

Firmographics
Name
Cellino
Legal name
Cellino
Website
https://cellinobio.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
101–250 employees
Short description
Cellino builds the AI-driven Nebula platform for scalable, autologous iPSC biomanufacturing of personalized regenerative cell therapies, serving biopharma partners, hospitals, and ultimately patients with chronic degenerative diseases.
Ownership category
akta.pro rank

Cellino industry classification

Industry
Product category
Regenerative Medicine Biomanufacturing
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAAABAG
Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)

Keywords

  • IPSC biomanufacturing
  • Regenerative medicine
  • Cell therapy manufacturing
  • Autologous cell therapy
  • Bioprocess automation

Where Cellino is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Cellino business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Infrastructure, Operations, Supply Chain, Marketing or Sales

Revenue model

  1. Government R&D grants (ARPA-H): Non-dilutive funding awarded by ARPA-H ($25M over five years under NEBULA) to support development of autonomous biomanufacturing; effectively functions as development-stage revenue tied to milestone delivery.
  2. Strategic co-development partnerships with biopharma: Cellino partners with biopharma companies (e.g., Karis Bio for cardiovascular iPSC therapy) to co-develop Nebula-powered autologous iPSC therapies, implying future milestone payments, licensing, or royalty streams.
  3. Future autologous iPSC therapy commercialization: Long-term commercial intent to deliver personalized regenerative therapies to patients at scale, targeting a per-line cost reduction from $1–$3 million to ~$10,000 by 2030, implying eventual per-treatment or per-line revenue.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractNot publicly disclosed; pre-commercial pricing roadmap targets ~$10,000 per autologous iPSC line by 2030 (down from current $1–$3M).

Go-to-market motion4 records

Distribution channels3 records

Marketing channels6 records

Cellino product offering

Product offering

Core offering

Cellino builds the Nebula™ platform, an AI-driven, closed-loop optical biomanufacturing system for producing autologous iPSC-based regenerative cell, tissue, and organ replacement therapies. The platform combines deep learning, label-free imaging, laser-based cell management, and the Cellinoverse in silico simulation environment, deployed through cassette-based hardware at centralized foundries or in hospitals. The company pursues co-development partnerships with biopharma and, longer term, intends to commercialize per-patient autologous therapies, targeting a reduction in cost per iPSC line from $1–3 million to ~$10,000 by 2030.

Product overview

Cellino offers a single unified automated biomanufacturing platform, the Nebula™ Platform, composed of tightly integrated modules: Deep Learning (AI algorithms for reproducible biomanufacturing), Cellinoverse (in silico simulation of bioprocess behavior), Laser Cell Management (laser-based cell-density control), and the Optical Bioprocess (closed-loop, image-guided bioprocess control). Together these modules power the Nebula-Powered iPSC Foundry, the first U.S.-based foundry for scalable autologous biomanufacturing, enabling patient-specific regenerative therapies for conditions such as Parkinson's, diabetes, heart disease, Alzheimer's, kidney disease, and spinal cord injury.

Differentiator

Problem solved

Functional benefit

Brands

  • Nebula: The company's proprietary AI-driven, modular, cassette-based biomanufacturing platform that compresses traditional infrastructure into scalable systems for producing personalized regenerative cell therapies (iPSC).

Products and services

  • Nebula™ Platform Cellino's flagship modular, cassette-based biomanufacturing platform that compresses traditional cell-therapy infrastructure to enable scalable, distributed production of autologous iPSC-based regenerative medicines, deployable as large foundries or in hospitals. It is sold/licensed through co-development partnerships with biopharma and is targeted at hospitals for future point-of-care manufacturing.
  • Nebula-Powered iPSC Foundry Facility-level deployment of the Nebula platform for scalable autologous biomanufacturing, launched as the U.S.'s first Nebula-Powered iPSC Foundry in February 2025. Operationalizes the Nebula platform as a centralized production and partnership hub serving biopharma co-development partners and future hospital customers.
  • NEBULA Hospital-Based Personalized Cell Therapy Manufacturing Program Government-funded program under ARPA-H NEBULA to enable hospitals and healthcare facilities to deploy Nebula cassettes for on-demand, point-of-care production of personalized autologous cell therapies targeting heart disease, Parkinson's, and diabetes.

Quantifiable outcome

  • Targeted cost reduction from $1–$3 million to approximately $10,000 per autologous iPSC line by 2030
  • +2 more outcomes

Companies that use Cellino

Customer profile

Segments3 records

Ideal customer profiles3 records

Cellino technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature6 records

Cellino partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core technology/clinical research partner, core co-development partner for first nebula-powered cardiovascular therapy and core co-development partner for spinal cord injury pipeline.

  • Polyphroncore technology/clinical research partnerStrategic or Co-development Partner · 7 April 2026Polyphron and Cellino jointly published results showing Polyphron's platform can manufacture structured human tissue across genetically diverse patient-derived iPSC lines without re-optimizing per donor, validating scalability of autologous tissue manufacturing via computational optimization.
  • Karis Biocore co-development partner for first nebula-powered cardiovascular therapyStrategic or Co-development Partner · 15 April 2025Cellino announced a partnership with Karis Bio to develop the first Nebula™-powered autologous iPSC therapy for cardiovascular disease. The partnership leverages Cellino's automated iPSC biomanufacturing platform to produce patient-specific regenerative therapies.
  • Matricelfcore co-development partner for spinal cord injury pipelineStrategic or Co-development Partner · 11 March 2025Cellino and Matricelf announced a global collaboration to scale personalized spinal cord injury treatments using Cellino's Nebula platform for autologous iPSC manufacturing combined with Matricelf's spinal cord regeneration technology.

Scale indicators8 records

Recent moves9 records

Expansion highlights6 records

Cellino competitors and assessment

Company assessment

Direct peers

  • ElevateBio: ElevateBio operates a hub-and-spoke cell and gene therapy platform combining process development and cGMP manufacturing capacity (BaseCamp) with internal therapeutic programs. Its integrated manufacturing-plus-pipeline model closely mirrors Cellino's foundry-plus-co-development strategy for regenerative cell therapies.
  • RoslinCT: RoslinCT (formerly Roslin Cells) is a cell therapy contract development and manufacturing organization specializing in iPSC-derived cell therapies, including clinical-grade iPSC line production. It directly competes with Cellino on scalable iPSC manufacturing for clinical and commercial regenerative medicine applications.
  • Ori Biotech: Ori Biotech is a London-based cell and gene therapy manufacturing platform company building automated, closed-system bioprocessing hardware for autologous and allogeneic therapies. It is one of the closest direct comparables to Cellino's Nebula platform given its focus on automation and scalability of personalized cell therapy manufacturing.
  • bit.bio: bit.bio is a UK-based synthetic biology company developing a precision cellular reprogramming technology (opti-ox) to produce defined human cell types at scale for research and therapeutic use. It is a direct peer in iPSC-derived cell therapy manufacturing technology, though with a different reprogramming modality.

Broad incumbents

  • Thermo Fisher Scientific: Thermo Fisher Scientific operates a sizable bioproduction and cell therapy services business, including cell therapy manufacturing capacity through its Patheon and Brammer Bio CDMO acquisitions. It is a broad incumbent competing across the full biomanufacturing stack where Cellino's Nebula platform aims to differentiate on automation and cost.
  • Lonza Group: Lonza is a Swiss global CDMO with one of the largest cell and gene therapy manufacturing footprints worldwide, including dedicated autologous cell therapy facilities. It serves as a broad incumbent that competes with Cellino by offering outsourced cell therapy manufacturing services to biopharma at industrial scale.
  • Cytiva (Danaher): Cytiva, a Danaher operating company, supplies bioprocessing equipment, consumables, and services for cell therapy manufacturing, including automation platforms. It overlaps with Cellino in the cell therapy bioprocess tooling market and is investing in closed, automated cell therapy manufacturing solutions.

Emerging players

  • Culture Biosciences: Culture Biosciences offers cloud-based, automated bioreactor infrastructure for bioprocess development and scale-up. It is an emerging player with thematic overlap to Cellino's automated biomanufacturing vision, particularly in applying software and AI to cell culture process optimization, though focused on microbial/mammalian bioprocess rather than autologous iPSC therapies.
  • Ginkgo Bioworks: Ginkgo Bioworks operates a synthetic biology platform combining automated lab infrastructure with cell programming capabilities for industrial and therapeutic applications. It is an emerging player with partial overlap to Cellino's automated, AI-driven cell engineering and biomanufacturing capabilities, though with a broader industrial biology scope.

Others

  • Vineti: Vineti provides a cell and gene therapy orchestration and supply chain platform that manages the workflow, chain of identity, and chain of custody for personalized cell therapies. It is an adjacent ecosystem participant rather than a direct competitor, but its orchestration role is complementary to Nebula's manufacturing focus and could be integrated with Cellino's platform.

Market position

Strengths5 records

Weaknesses2 records

Competitive moat5 records

Key risks7 records

Key highlights8 records

Customer concentration

Cellino social profiles

Digital presence

Cellino compliance and trust

Trust signal

Compliance1 record

Cellino financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cellino leadership team

Management profile

Number of profiles

Profiles7 records

Cellino subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Cellino funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cellino M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellino

What does Cellino do?

Cellino builds the Nebula™ platform, an AI-driven, closed-loop optical biomanufacturing system for producing autologous iPSC-based regenerative cell, tissue, and organ replacement therapies. The platform combines deep learning, label-free imaging, laser-based cell management, and the Cellinoverse in silico simulation environment, deployed through cassette-based hardware at centralized foundries or in hospitals. The company pursues co-development partnerships with biopharma and, longer term, intends to commercialize per-patient autologous therapies, targeting a reduction in cost per iPSC line from $1–3 million to ~$10,000 by 2030.

Is Cellino a public or private company?

Cellino is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cellino founded?

Cellino was founded in 2017. It employs 101 to 250 people.

Where is Cellino based?

Cellino is headquartered in Cambridge, United States, in the North America region.

How does Cellino make money?

Three revenue lines are on record. Government R&D grants (ARPA-H) is the primary driver. The others are strategic co-development partnerships with biopharma and future autologous iPSC therapy commercialization.

Who are Cellino's main competitors?

Direct peers on record are ElevateBio, RoslinCT, Ori Biotech and bit.bio. Broad incumbents are Thermo Fisher Scientific, Lonza Group and Cytiva (Danaher). Emerging players are Culture Biosciences and Ginkgo Bioworks. Vineti is listed as an others.

Does Cellino have an API?

No public API is recorded for Cellino.

What industry is Cellino in?

Cellino's product category is Regenerative Medicine Biomanufacturing. Its primary akta.pro industry code is HLAAABAG, Cell Therapy Manufacturing Platforms & Automation (closed systems, bioreactors, fill-finish), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AmbitoCongelar el sistema inmune: la propuesta de Cellino para preservar células por u$s5.000Cellino's Reservoir service freezes immune cells from blood samples for $5,000, with $270 annual maintenance. The company, backed by over $96 million, offers the service in US clinics, but medical applications remain under development.Business Wire BlogIntroducing Reservoir: Preserve Your Immune Cells at Their Biological YoungestReservoir launched a personal cell preservation service that lets adults preserve their immune cells via a standard blood draw, with cells stored below -150°C at an FDA-registered facility. The service is available through partner clinics in San Francisco, Boston, Los Angeles, and New York City, with in-home appointments launching in select markets. Reservoir is built by Cellino, which has raised over $96 million in venture funding.AthletechnewsCellino Launches $5K Immune Cell Banking Service for Longevity-Focused ConsumersCellino launched Reservoir, a service for adults to cryopreserve immune cells via blood draw, with samples stored below -150°C. Pricing starts at $5,000 plus $270 annually, and the service is available through partner clinics in select markets.Longevity.TechnologyCellino team launches immune cell banking serviceReservoir, a Cellino subsidiary, launched a service to bank adult immune cells via a routine blood draw, cryopreserving five vials of PBMCs. The service is available through partner clinics in Boston, San Francisco, Los Angeles, and New York City, with at-home draws launching soon. Pricing and future therapeutic uses are not disclosed.ForbesYou Can Now Preserve Your Immune Cells For $5,000 In Case They’re Helpful In The FutureCellino launched a service to store immune cells from a blood draw for $5,000 plus $270 annually. The service, offered through subsidiary Reservoir, is not marketed for any disease treatment, and the company has raised $96 million in funding.Tracxn2026 Funding Rounds & List of InvestorsCellino has raised multiple funding rounds, including a Series A in September 2024 and earlier seed rounds in 2017-2021. The rounds show increasing post-money valuations, with the latest at $9,554,114. Lead investors include Felicis Ventures and Humboldt Fund.BCC ResearchAI in Bioprinting: Key Benefits and ChallengesAn industry analysis examines how artificial intelligence is reshaping bioprinting, covering applications in tissue engineering, drug discovery, personalized therapies and quality assurance. It cites corporate AI investment of $252.3 billion in 2024, with private investment up 44.5% year-over-year, and funding milestones including Aspect Biosystems' $115 million Series B and Cellino Biotech's $25 million ARPA-H award. The report identifies regulatory hurdles, talent shortages, data privacy and infrastructure gaps as persistent constraints.GlobeNewswireAI-Driven Bioprinting Emerges as a High-Conviction Investment Theme as Corporate AI Spending Surpasses $252 BillionBCC Research released a qualitative report on AI's impact on the bioprinting market, citing corporate AI investment of $252.3 billion in 2024, with private investment up 44.5% year-over-year. The U.S. led with $109.1 billion, compared to China's $9.3 billion, and the report names Aspect Biosystems, Cellino Biotech, Morphocell and others.BCC ResearchAI-Powered Wound Care: Where Machine Learning Meets HealingAI technologies are increasingly being applied to wound care, with smartphone-enabled imaging platforms, smart sensor-embedded dressings, and machine learning algorithms shifting the field from reactive treatment toward predictive, personalized care. Corporate AI investment reached $252.3 billion globally in 2024, with companies including Swift Medical ($43 million raised), Spectral AI ($22.6 million), and Cellino Biotech ($25 million from ARPA-H) securing significant funding for wound care applications. These technologies, ranging from computer vision wound assessment to AI-guided bioprinting, are transitioning from laboratory development toward clinical implementation.BarchartSpinal Cord Injury Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Nipro Corp, Kringle Pharma, Abbvie, Neuroplast, Mitsubishi Tanabe Pharma America, Kringle PharmaDelveInsight's Spinal Cord Injury market report projects the market will grow from approximately USD 350 million in 2025 at an 18.3% CAGR through 2036, driven by advances in regenerative medicine and neurotechnology. Key recent developments include ONWARD Medical's FDA 510(k) clearance for home use of its ARC-EX System and XellSmart Biopharmaceutical's dual NMPA/FDA approvals for an off-the-shelf iPSC-derived neural regenerative cell therapy. The report covers pipeline therapies from multiple companies including Lineage Cell Therapeutics, Cellino, Matricelf, and NurExone Biologic advancing through preclinical and clinical stages.